What question did this study set out to answer?

To evaluate the 96-week efficacy, safety, and patient-reported outcomes of switching to dolutegravir plus rilpivirine in virologically suppressed adults with HIV-1 harboring historic K103N resistance mutations.

January 22, 2026AIDS

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation

View Full Paper

Ask AI

Bookmark

Authors

GMGraeme Moyle LALambert Assoumou NCNathalie De Castro

Discussion

Member takes

Overview

Randomized trial demonstrates sustained virological suppression after switching to dolutegravir and rilpivirine in HIV-1 with prior K103N mutations, indicating durable two-drug regimen efficacy.

Key Points

To evaluate the 96-week efficacy, safety, and patient-reported outcomes of switching to dolutegravir plus rilpivirine in virologically suppressed adults with HIV-1 harboring historic K103N resistance mutations.
Open-label, parallel, two-arm randomized trial conducted across 32 sites in seven European countries (WISARD trial).
Enrolled 140 treatment-experienced participants with HIV-1 RNA <50 copies/ml and documented K103N mutations, randomized 2:1 to immediate switch (DTG/RPV-I, n=95) or deferred switch at week 48 (DTG/RPV-D, n=45).
Virological suppression at week 96 was 84.2% in the immediate switch group versus 73.3% in the deferred switch group (difference +10.9%, 95% CI -4 to +25.8; P = 0.168).
Confirmed virological failure occurred in 8 participants through week 96 (4 by week 48, 4 between weeks 48 and 96); only one sample successfully amplified, showing no emergent DTG- or RPV-associated resistance mutations.
Serious adverse events were infrequent with none attributed to study medication, and health-related quality of life, treatment satisfaction, and sleep quality remained stable over time in both groups.

Cite This Study

Moyle et al. (2026) studied this question.

synapsesocial.com/papers/6aacfc65b488817de87c5d51 https://doi.org/10.1097/qad.0000000000004451

View Full Paper

Ask AI

Bookmark

January 22, 2026AIDS

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation

View Full Paper

Ask AI

Bookmark

Authors

GMGraeme Moyle LALambert Assoumou NCNathalie De Castro

Discussion

Member takes

Overview

Randomized trial demonstrates sustained virological suppression after switching to dolutegravir and rilpivirine in HIV-1 with prior K103N mutations, indicating durable two-drug regimen efficacy.

Key Points

To evaluate the 96-week efficacy, safety, and patient-reported outcomes of switching to dolutegravir plus rilpivirine in virologically suppressed adults with HIV-1 harboring historic K103N resistance mutations.
Open-label, parallel, two-arm randomized trial conducted across 32 sites in seven European countries (WISARD trial).
Enrolled 140 treatment-experienced participants with HIV-1 RNA <50 copies/ml and documented K103N mutations, randomized 2:1 to immediate switch (DTG/RPV-I, n=95) or deferred switch at week 48 (DTG/RPV-D, n=45).
Virological suppression at week 96 was 84.2% in the immediate switch group versus 73.3% in the deferred switch group (difference +10.9%, 95% CI -4 to +25.8; P = 0.168).
Confirmed virological failure occurred in 8 participants through week 96 (4 by week 48, 4 between weeks 48 and 96); only one sample successfully amplified, showing no emergent DTG- or RPV-associated resistance mutations.
Serious adverse events were infrequent with none attributed to study medication, and health-related quality of life, treatment satisfaction, and sleep quality remained stable over time in both groups.

Cite This Study

Moyle et al. (2026) studied this question.

synapsesocial.com/papers/6aacfc65b488817de87c5d51 https://doi.org/10.1097/qad.0000000000004451

View Full Paper

Ask AI

Bookmark